Licensing insulin first, then expanding the platform
rBIO’s business model is to complete scale-up of its insulin manufacturing process, become process-ready to license, and work with qualified partners in priority regional and global markets.
Development and licensing roadmap
rBIO is advancing a focused plan to move from early process development to commercial-scale readiness and licensing.
The company’s initial focus is insulin, with expansion potential across insulin analogs and other peptide drugs.
| STAGE | STATUS | PURPOSE | ||
|---|---|---|---|---|
| 20L pilot | Completed | Establish early process performance | ||
| Exploratory animal study | Completed | Support biological validation | ||
| 1,000L scale-up | Next planned milestone | Move toward commercial-scale process development | ||
| Product-ready | Target milestone | Become process-ready to license | ||
| Licensing | Target commercial model | License insulin first; expand by geography and peptide category |
Insulin first
Insulin is rBIO’s first manufacturing focus because it is a large, essential peptide-drug market with persistent cost, access, and supply challenges.
rBIO’s current objective is to complete process scale-up and licensing readiness before expanding the platform to other peptides.
Our strategy
rBIO intends to license insulin first, expand across priority geographies, and then extend the platform to additional peptide drugs.
License insulin first
Insulin is rBIO’s first target because it combines large market needs, persistent manufacturing inefficiencies, and clear partner interest.License globally
The company’s model is designed for regional and strategic partners in priority markets: Mexico, U.S.A., EU, India, and MENAExpand to other peptides
After insulin, rBIO intends to extend the platform to additional peptide drugs where manufacturing output, cost, and supply stability remain important.
With every licensing opportunity, rBIO’s goal is to improve manufacturing efficiency, support broader access, and help partners bring essential peptide drugs to market more effectively.
Discuss licensing or investment
rBIO is seeking conversations with prospective investors, licensing partners, drug manufacturers, CDMOs, distributors, and strategic pharma organizations interested in insulin and peptide-drug manufacturing.